Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
102.3 USD | +0.21% | +4.72% | +1.36% |
May. 10 | Novartis’ Scemblix Gets Third US FDA Breakthrough Therapy Designation | MT |
May. 10 | Novartis Gets FDA Breakthrough Therapy Designation for Scemblix | DJ |
Financials (USD)
Sales 2024 * | 48.96B | Sales 2025 * | 50.79B | Capitalization | 208B |
---|---|---|---|---|---|
Net income 2024 * | 10.5B | Net income 2025 * | 12.07B | EV / Sales 2024 * | 4.51 x |
Net Debt 2024 * | 12.88B | Net Debt 2025 * | 11.28B | EV / Sales 2025 * | 4.31 x |
P/E ratio 2024 * |
20.2
x | P/E ratio 2025 * |
17.3
x | Employees | 76,057 |
Yield 2024 * |
3.55% | Yield 2025 * |
3.68% | Free-Float | 85.22% |
Latest transcript on Novartis AG
1 day | +1.89% | ||
1 week | +4.97% | ||
Current month | +5.12% | ||
1 month | +9.17% | ||
3 months | +1.56% | ||
6 months | +9.15% | ||
Current year | +1.12% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 04-12-31 | |
Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 12-12-31 |
Simon Moroney
BRD | Director/Board Member | 65 | 20-02-27 |
Chairman | 68 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
8.01% | 13 M€ | -.--% | ||
1.52% | 9 M€ | -4.31% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 102.4 | +0.26% | 787 477 |
24-05-10 | 102.1 | +1.89% | 1,843,451 |
24-05-09 | 100.2 | +0.61% | 1,384,529 |
24-05-08 | 99.6 | +0.53% | 1,153,281 |
24-05-07 | 99.07 | +1.37% | 1,159,818 |
Delayed Quote Nyse, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.38% | 684B | |
+29.16% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.31% | 240B | |
-7.73% | 200B | |
+7.68% | 166B | |
-2.71% | 159B |
- Stock Market
- Equities
- NOVN Stock
- NVS Stock